Search results for "Intensive Care Medicine"

showing 10 items of 2228 documents

Unconventional diagnostic tests for Lyme borreliosis: a systematic review

2019

Abstract Background Lyme borreliosis (LB) diagnosis currently relies mainly on serological tests and sometimes PCR or culture. However, other biological assays are being developed to try to improve Borrelia-infection diagnosis and/or monitoring. Objectives To analyse available data on these unconventional LB diagnostic assays through a systematic literature review. Methods We searched PubMed and Cochrane Library databases according to the PRISMA-DTA method and the Cochrane Handbook for Systematic Reviews of Interventions. We analysed controlled and uncontrolled studies (published 1983–2018) on biological tests for adults to diagnose LB according to the European Study Group for Lyme Borrelio…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty030106 microbiologyClinical assessmentMEDLINEReviewCochrane LibrarySensitivity and SpecificitySerology03 medical and health sciences0302 clinical medicineMeta-Analysis as Topic[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineHumansSerologic Tests[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030212 general & internal medicineIntensive care medicineComputingMilieux_MISCELLANEOUSLyme borreliosisLyme Disease[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesClinical Laboratory TechniquesLyme borreliosisbusiness.industryDiagnostic testGeneral Medicinemedicine.diseasebacterial infections and mycoses[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthInfectious DiseasesSystematic reviewDiagnostic testsBorrelia burgdorferi[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyXenodiagnosesbusinessNeuroborreliosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.

2019

Introduction: Infections are among the most frequent complications in patients with hematological and oncological diseases. They might be classified as fever of unknown origin and microbiologically or clinically documented infections. Optimal duration of antimicrobial treatment is still unclear in these patients.Areas covered: We provide an overview on the management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.Expert opinion: Patients with febrile high-risk neutropenia should be treated empirically with an anti-pseudomonal agent such as piperacillin/tazobactam. Several clinical studies support the assumption that the primary antibiotic regime…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyAntifungal Agents030106 microbiologyNeutropeniaMicrobiologyTazobactam03 medical and health sciencesAntimicrobial Stewardship0302 clinical medicineAnti-Infective AgentsVirologyMedicineHumans030212 general & internal medicineFever of unknown originIntensive care medicineFebrile Neutropeniabusiness.industryDrug Resistance Microbialmedicine.diseaseAntimicrobialDrug Resistance MultipleDiscontinuationAnti-Bacterial AgentsInfectious DiseasesDrug Therapy CombinationbusinessFebrile neutropeniaDe-escalationmedicine.drugPiperacillinExpert review of anti-infective therapy
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

2021

INTRODUCTION: The COVID-19 pandemic has dramatically challenged the national health systems worldwide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified weekly administration regimens, thus representing a promising option for the outpatient treatment of Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and infective endocarditis. AREAS COVERED: A search in the literature using validated keyword…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classProsthetic joint030106 microbiologyAntibioticsGram-Positive Bacterial InfectionABSSSIsMicrobiologyDrug Administration Scheduleosteomyelitis.endocarditi03 medical and health sciencesABSSSIs; COVID-19; dalbavancin; endocarditis; Gram-positive; long-acting; osteomyelitisGram-positive0302 clinical medicineVirologyPandemicAnti-Bacterial AgentmedicineAmbulatory CareAnimalsHumans030212 general & internal medicineIntensive care medicineGram-Positive Bacterial Infectionsbusiness.industryAnimalOsteomyelitisDalbavancinCOVID-19osteomyelitisSkin Diseases Bacteriallong-actingABSSSImedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesInfective endocarditisSkin structureendocarditisosteomyelitiTeicoplaninbusinessdalbavancinHuman
researchProduct

Myocarditis in Mediterranean spotted fever: a case report and a review of the literature

2016

Introduction: Mediterranean spotted fever (MSF) is a tick-borne acute febrile disease caused by Rickettsia conorii. Most cases follow a benign course, with a case fatality rate of 3–7 % among hospitalized patients. Complications are described mainly in adult patients and include hepatic, renal, neurological and cardiac impairment. Among cardiac complications, pericarditis, myocarditis and heart rhythm disorders are uncommon complications in MSF and only a few cases have been reported in the literature. Case Presentation: We describe a new case of acute myocarditis complicating MSF in an immunocompetent adult patient without risk factors for severe MSF. Conclusion: Myocarditis is an uncommon…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyPediatricsMyocarditisHeart rhythm disorders030106 microbiologyCase ReportDiseaseMediterraneanMicrobiology03 medical and health sciencesPericarditisZoonosis0302 clinical medicineCase fatality rateMedicinespotted030212 general & internal medicineconoriiIntensive care medicineBlood/Heart and Lymphaticsfeverbiologybusiness.industryMortality rateMediterranean; conorii; fever; myocarditis; rickettsia; spottedmedicine.diseasebiology.organism_classificationrickettsiaSpotted fevermyocarditimyocarditisbusinessRickettsia conoriiJMM Case Reports
researchProduct

The BioFireFilmArray enables point of care diagnostic in neonatal parechovirus meningitis.

2017

Sir,We read with great interest a report in the present journal on the application of broad-range PCR combined with DNA sequencing for detection of bacteria in cerebrospinal fluid (CSF) [1]. This m...

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyPoint-of-Care Systems030106 microbiologyMEDLINEParechovirusDNA sequencingInfant Newborn Diseases03 medical and health sciencesCerebrospinal fluidMedicineHumansMeningitisIntensive care medicinePicornaviridae InfectionsPoint of carePicornaviridae InfectionsGeneral Immunology and Microbiologybiologybusiness.industryInfant NewbornGeneral Medicinemedicine.diseasebiology.organism_classificationhumanitiesInfectious DiseasesParechovirusbusinessMeningitisInfectious diseases (London, England)
researchProduct

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

2019

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.

0301 basic medicineOccult HBV infectionHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaHbv reactivationMEDLINEHBV reactivationOBImedicine.disease_cause03 medical and health sciences0302 clinical medicineHBV S variantRisk FactorsmedicineHumansHepatitis B AntibodiesIntensive care medicineComputingMilieux_MISCELLANEOUSHepatitis B virusHepatitis B Surface AntigensHepatologyHBV cccDNALiver Neoplasmsvirus diseasesHBV cccDNA; HBV reactivation; HBV S variants; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infectionHBV S variantsHepatitis Bmedicine.diseaseOccultdigestive system diseases3. Good healthHBV S variants; HBV cccDNA; HBV reactivation; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infection030104 developmental biologyLiverHepatocellular carcinomaDNA Viral030211 gastroenterology & hepatologyHBV transmission[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

EGFR inhibition in NSCLC: New findings…. and opened questions?

2017

The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent f…

0301 basic medicineOncologyLung Neoplasmsmedicine.medical_treatmentAfatinibResistanceTreatment of lung cancerTargeted therapyTargeted therapyAntineoplastic Agent0302 clinical medicineEpidermal growth factorEpidermal growth factor receptorMolecular Targeted TherapybiologyHematologyTKIErbB ReceptorsOncology030220 oncology & carcinogenesisErlotinibReceptorHumanmedicine.drugmedicine.medical_specialtyEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEGFRProtein Kinase InhibitorAntineoplastic Agents03 medical and health sciencesGefitinibInternal medicinemedicineHumansLiquid biopsyIntensive care medicineProtein Kinase InhibitorsEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor; Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEpidermal Growth FactorLiquid biopsybusiness.industryrespiratory tract diseasesLung Neoplasm030104 developmental biologyTKIsMutationbiology.proteinReceptor Epidermal Growth FactorGeriatrics and Gerontologybusiness
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Legume consumption and risk of all-cause, cardiovascular, and cancer mortality in the PREDIMED study.

2018

BACKGROUND & AIMS: Limited prospective studies have examined the association between legumes consumption and mortality, whereas scarce, if at all, previous studies have evaluated such associations taking into consideration specific grain legumes. We aimed to investigate the association between total legumes consumption and grain legumes species (dry beans, chickpeas, lentils, and fresh peas) with all-cause, cardiovascular disease (CVD), cancer and other-cause mortality among elderly Mediterranean individuals at high CVD risk. METHODS: We prospectively assessed 7216 participants from the PREvención con DIeta MEDiterránea study. Dietary intake was assessed at baseline and yearly during follow…

0301 basic medicinePREDIMEDMaleDiseaseCritical Care and Intensive Care MedicineLower riskCardiovascularDiet MediterraneanCohort Studies03 medical and health sciencesRisk FactorsNeoplasmsMedicineHumansProspective StudiesMortalityCàncerProspective cohort studyLegumeCancerAgedConsumption (economics)Aged 80 and over030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryHazard ratioCancerFabaceaeMiddle Agedmedicine.diseaseLegumesConfidence intervalCardiovascular DiseasesSpainFemalebusinessllegums -- ConsumDemographyFollow-Up Studies
researchProduct